Jilin Jian Yisheng Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 13.32%

Jilin Jian Yisheng Pharmaceutical Co Ltd (002566) has an Asset Resilience Ratio of 13.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Jilin Jian Yisheng Pharmaceutical Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥400.57 Million
≈ $58.62 Million USD Cash + Short-term Investments

Total Assets

CN¥3.01 Billion
≈ $439.90 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how Jilin Jian Yisheng Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 002566 net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Jilin Jian Yisheng Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Jilin Jian Yisheng Pharmaceutical Co Ltd market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥400.57 Million 13.32%
Total Liquid Assets CN¥400.57 Million 13.32%

Asset Resilience Insights

  • Moderate Liquidity: Jilin Jian Yisheng Pharmaceutical Co Ltd has 13.32% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Jilin Jian Yisheng Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jilin Jian Yisheng Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 84.34%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
Biotechnology 0.02%
Novavax Inc
NASDAQ:NVAX
Biotechnology 53.87%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Jilin Jian Yisheng Pharmaceutical Co Ltd (2006–2025)

The table below shows the annual Asset Resilience Ratio data for Jilin Jian Yisheng Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 17.15% CN¥507.57 Million
≈ $74.27 Million
CN¥2.96 Billion
≈ $433.09 Million
+1.68pp
2024-12-31 15.47% CN¥459.67 Million
≈ $67.26 Million
CN¥2.97 Billion
≈ $434.70 Million
+12.09pp
2023-12-31 3.38% CN¥102.98 Million
≈ $15.07 Million
CN¥3.05 Billion
≈ $445.83 Million
+1.36pp
2022-12-31 2.02% CN¥59.84 Million
≈ $8.76 Million
CN¥2.97 Billion
≈ $434.11 Million
-0.43pp
2021-12-31 2.45% CN¥70.16 Million
≈ $10.27 Million
CN¥2.86 Billion
≈ $419.15 Million
+2.30pp
2017-12-31 0.15% CN¥4.00 Million
≈ $585.33K
CN¥2.65 Billion
≈ $388.29 Million
-1.10pp
2015-12-31 1.25% CN¥33.00 Million
≈ $4.83 Million
CN¥2.63 Billion
≈ $385.40 Million
-2.04pp
2014-12-31 3.29% CN¥82.00 Million
≈ $12.00 Million
CN¥2.49 Billion
≈ $364.42 Million
+3.21pp
2006-12-31 0.08% CN¥269.00K
≈ $39.36K
CN¥338.04 Million
≈ $49.47 Million
--
pp = percentage points

About Jilin Jian Yisheng Pharmaceutical Co Ltd

SHE:002566 China Biotechnology
Market Cap
$311.88 Million
CN¥2.13 Billion CNY
Market Cap Rank
#14723 Global
#4394 in China
Share Price
CN¥6.44
Change (1 day)
-0.92%
52-Week Range
CN¥6.44 - CN¥9.05
All Time High
CN¥19.38
About

Jilin Jian Yisheng Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, wholesale, retail, import, and export of pharmaceutical products in China. The company offers paper packaging products; drugs comprising capsules, injections, tablets, granules, and other drug products; cosmetics; ginseng products; bee products; and food products comprisi… Read more